An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 270 participants.

Also called NCT03749447

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 270 participants (enrolled count) (from the registry)
Sponsor
  • Biogen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03749447
  • EudraCT 2018-003253-24
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, France, Japan, Puerto Rico, Spain (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT03749447. Allocation not applicable; no masking; primary purpose treatment. Start 2019-03-08 (actual); primary completion 2023-08-23 (actual). Results posted on 2024-03-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)
Acronym
EAGLE
Condition
Chronic Kidney Diseases
Condition
Alport Syndrome
Condition
Autosomal Dominant Polycystic Kidney
Intervention (Drug)
Bardoxolone methyl
Lead sponsor
Biogen (class: industry)

Record details

Record id
cardio:ct-nct03749447
Content hash
fb51cf2ae601edc9ed28710b2c67cbd14d6d1a6648d14a2a3f1e9aec7fc938a3